Positive results from pancreatic treatment trials boosted drug developer Immuneering's (IMRX.US) stock by 58% after hours.

On Thursday, drug developer Immuneering (IMRX.US) reported positive data results from a phase 2a trial of its candidate drug IMM-1-104 in combination with modified gemcitabine/albumin-bound paclitaxel as a first-line treatment for pancreatic cancer. The company's stock price surged after hours, up 58% at the time of writing. According to a statement, the company reported that the first two out of five patients observed in the study achieved complete or partial responses, with an overall initial response rate of 40% and a disease control rate of 80%. Immuneering stated that it expects to receive more data by the end of this year.